Thalassemia and malignancies : Updates from the literature
© 2023 The New York Academy of Sciences..
Thalassemia management has undergone significant development with the advancement in iron chelation therapy, which has led to a prolonged life expectancy. This has been accompanied by the emergence of several new morbidities and chronic diseases, including cancer. Over the years, multiple cases of solid and hematologic malignancies in thalassemia patients have been reported in the literature, with no clear mechanism for the development of cancer in these patients despite a number of potential mechanisms. However, the results of many studies have been contradictory regarding the risk of development of malignancies in thalassemia. The present review aims to discuss the available data on cancer and thalassemia in the literature, with the latest updates regarding possible malignancy development mechanisms, risks, and the most commonly reported types.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1529 |
|---|---|
| Enthalten in: |
Annals of the New York Academy of Sciences - 1529(2023), 1 vom: 01. Nov., Seite 14-20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hodroj, Mohammad Hassan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Iron Chelating Agents |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/nyas.15061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361744595 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361744595 | ||
| 003 | DE-627 | ||
| 005 | 20240214232804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/nyas.15061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM361744595 | ||
| 035 | |a (NLM)37676814 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hodroj, Mohammad Hassan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thalassemia and malignancies |b Updates from the literature |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The New York Academy of Sciences. | ||
| 520 | |a Thalassemia management has undergone significant development with the advancement in iron chelation therapy, which has led to a prolonged life expectancy. This has been accompanied by the emergence of several new morbidities and chronic diseases, including cancer. Over the years, multiple cases of solid and hematologic malignancies in thalassemia patients have been reported in the literature, with no clear mechanism for the development of cancer in these patients despite a number of potential mechanisms. However, the results of many studies have been contradictory regarding the risk of development of malignancies in thalassemia. The present review aims to discuss the available data on cancer and thalassemia in the literature, with the latest updates regarding possible malignancy development mechanisms, risks, and the most commonly reported types | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a malignancies | |
| 650 | 4 | |a non-transfusion-dependent thalassemia | |
| 650 | 4 | |a thalassemia | |
| 650 | 4 | |a transfusion-dependent thalassemia | |
| 650 | 7 | |a Iron Chelating Agents |2 NLM | |
| 700 | 1 | |a Taher, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the New York Academy of Sciences |d 1945 |g 1529(2023), 1 vom: 01. Nov., Seite 14-20 |w (DE-627)NLM000012823 |x 1749-6632 |7 nnns |
| 773 | 1 | 8 | |g volume:1529 |g year:2023 |g number:1 |g day:01 |g month:11 |g pages:14-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/nyas.15061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1529 |j 2023 |e 1 |b 01 |c 11 |h 14-20 | ||